Results 241 to 250 of about 49,931 (273)
Some of the next articles are maybe not open access.
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.
Nutrition reviews, 2008This article reviews surrogate endpoints and emerging biomarkers that were discussed at the annual "Cardiovascular Biomarkers and Surrogate Endpoints" symposium cosponsored by the US Food and Drug Administration (FDA) and the Montreal Heart Institute.
Crystal M, Rasnake +2 more
openaire +3 more sources
Surrogate Endpoints in Suicide Research
Suicide and Life-Threatening Behavior, 2010Surrogate endpoints frequently substitute for rare outcomes in research. The ability to learn about completed suicides by investigating more readily available and proximate outcomes, such as suicide attempts, has obvious appeal. However, concerns with surrogates from the statistical science perspective exist, and mounting evidence from psychometric ...
Hal S, Wortzel +4 more
openaire +2 more sources
Surrogate Endpoints of Clinical Benefit
2012Despite several decades of intensive clinical and biological research and significant progress in primary prevention, screening, diagnosis, prognosis, and treatment, cancer is still the second most common cause of death in developed countries, accounting for about one-fourth of total deaths [1].
G. Ciccone, BALDI, ILEANA
openaire +2 more sources
Endpoints: Surrogates and Composites
Cardiovascular Revascularization Medicine, 2022openaire +2 more sources
Bulletin du cancer, 1999
The main endpoint of a phase III trial in oncology must be relevant clinically. In practice, this endpoint is either the disease-free or the overall survival, which requires both long term follow-up and a large number of patients. In phase II trials, it is essential to proceed rapidly, and one therefore uses a surrogate endpoint.
openaire +1 more source
The main endpoint of a phase III trial in oncology must be relevant clinically. In practice, this endpoint is either the disease-free or the overall survival, which requires both long term follow-up and a large number of patients. In phase II trials, it is essential to proceed rapidly, and one therefore uses a surrogate endpoint.
openaire +1 more source